|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07D 205/04 | |
| A61K 31/397 | |||
| A61P 29/00 | |||
| A61P 31/06 | |||
| A61P 31/08 | |||
| A61P 21/00 |
| (11) | Patento numeris | 2379499 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 09793424.4 |
| Europos patento paraiškos padavimo data | 2009-12-17 | |
| (97) | Europos patento paraiškos paskelbimo data | 2011-10-26 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2014-04-09 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2009/068352 |
| Data | 2009-12-17 |
| (87) | Numeris | WO 2010/080455 |
| Data | 2010-07-15 |
| (30) | Numeris | Data | Šalis |
| 203051 P | 2008-12-18 | US |
| (72) |
DE LA CRUZ, Marilyn, US
KARPINSKI, Piotr, H., US
LIU, Yugang, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | Hydrochloride salt of 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidine-3-carboxylic acid |
| Hydrochloride salt of 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidine-3-carboxylic acid |